Ten-Year Change in Plasma Amyloid beta Levels and Late-Life Cognitive Decline Export

@article{citeulike:5950456, abstract = {Background Plasma levels of amyloid {beta} peptide (A{beta}) are potential biomarkers of early cognitive impairment and decline and of Alzheimer disease risk. Objective To relate midlife plasma A{beta} measures and 10-year change in plasma A{beta} measures since midlife to late-life cognitive decline. Design Prospective study of a population-based sample. Setting Academic research. Participants Plasma A{beta}40 and A{beta}42 levels were measured in 481 Nurses' Health Study participants in late midlife (mean age, 63.6 years) and again 10 years later (mean age, 74.6 years). Cognitive testing also began 10 years after the initial blood draw. Participants completed 3 repeated telephone-based assessments (mean span, 4.1 years). Multivariable linear mixed-effects models were used to estimate relations of midlife plasma A{beta}40 to A{beta}42 ratios and A{beta}42 levels to late-life cognitive decline, as well as relations of 10-year change in A{beta}40 to A{beta}42 ratios and A{beta}42 levels to cognitive decline. Main Outcome Measures The 3 primary outcomes were the Telephone Interview for Cognitive Status (TICS) findings, a global score averaging the results of all tests (TICS, immediate and delayed verbal recall, category fluency, and attention), and a verbal memory score averaging the results of 4 tests of verbal recall. Results Higher midlife plasma A{beta}40 to A{beta}42 ratios were associated with worse late-life decline on the global score (P = .04 for trend). Furthermore, increase in A{beta}40 to A{beta}42 ratios since midlife predicted greater decline in the global score (P = .03 for trend) and in the TICS (P = .02 for trend). There was no association of cognitive decline with midlife plasma A{beta}42 levels alone or with change in A{beta}42 levels since midlife. Conclusion In this large community-dwelling sample, higher plasma A{beta}40 to A{beta}42 ratios in late midlife and increases in A{beta}40 to A{beta}42 ratios 10 years later were significantly associated with greater decline in global cognition at late life. 10.1001/archneurol.2009.207}, author = {Okereke, Olivia I. and Xia, Weiming and Selkoe, Dennis J. and Grodstein, Francine}, citeulike-article-id = {5950456}, citeulike-linkout-0 = {http://dx.doi.org/10.1001/archneurol.2009.207}, citeulike-linkout-1 = {http://archneur.ama-assn.org/content/66/10/1247.abstract}, citeulike-linkout-2 = {http://archneur.ama-assn.org/content/66/10/1247.full.pdf}, citeulike-linkout-3 = {http://view.ncbi.nlm.nih.gov/pubmed/19822780}, citeulike-linkout-4 = {http://www.hubmed.org/display.cgi?uids=19822780}, day = {1}, doi = {10.1001/archneurol.2009.207}, journal = {Arch Neurol}, keywords = {amyloid, cjd, gcjd}, month = {October}, number = {10}, pages = {1247--1253}, posted-at = {2009-10-16 11:47:48}, priority = {4}, title = {Ten-Year Change in Plasma Amyloid {beta} Levels and Late-Life Cognitive Decline}, url = {http://dx.doi.org/10.1001/archneurol.2009.207}, volume = {66}, year = {2009} }

TY - JOUR ID - citeulike:5950456 L3 - citeulike-article-id:5950456 N2 - Background Plasma levels of amyloid {beta} peptide (A{beta}) are potential biomarkers of early cognitive impairment and decline and of Alzheimer disease risk. Objective To relate midlife plasma A{beta} measures and 10-year change in plasma A{beta} measures since midlife to late-life cognitive decline. Design Prospective study of a population-based sample. Setting Academic research. Participants Plasma A{beta}40 and A{beta}42 levels were measured in 481 Nurses' Health Study participants in late midlife (mean age, 63.6 years) and again 10 years later (mean age, 74.6 years). Cognitive testing also began 10 years after the initial blood draw. Participants completed 3 repeated telephone-based assessments (mean span, 4.1 years). Multivariable linear mixed-effects models were used to estimate relations of midlife plasma A{beta}40 to A{beta}42 ratios and A{beta}42 levels to late-life cognitive decline, as well as relations of 10-year change in A{beta}40 to A{beta}42 ratios and A{beta}42 levels to cognitive decline. Main Outcome Measures The 3 primary outcomes were the Telephone Interview for Cognitive Status (TICS) findings, a global score averaging the results of all tests (TICS, immediate and delayed verbal recall, category fluency, and attention), and a verbal memory score averaging the results of 4 tests of verbal recall. Results Higher midlife plasma A{beta}40 to A{beta}42 ratios were associated with worse late-life decline on the global score (P = .04 for trend). Furthermore, increase in A{beta}40 to A{beta}42 ratios since midlife predicted greater decline in the global score (P = .03 for trend) and in the TICS (P = .02 for trend). There was no association of cognitive decline with midlife plasma A{beta}42 levels alone or with change in A{beta}42 levels since midlife. Conclusion In this large community-dwelling sample, higher plasma A{beta}40 to A{beta}42 ratios in late midlife and increases in A{beta}40 to A{beta}42 ratios 10 years later were significantly associated with greater decline in global cognition at late life. 10.1001/archneurol.2009.207 IS - 10 JF - Arch Neurol EP - 1253 TI - Ten-Year Change in Plasma Amyloid {beta} Levels and Late-Life Cognitive Decline VL - 66 SP - 1247 KW - amyloid KW - cjd KW - gcjd AU - Okereke, Olivia AU - Xia, Weiming AU - Selkoe, Dennis AU - Grodstein, Francine PY - 2009/10/01/ UR - http://dx.doi.org/10.1001/archneurol.2009.207 ER -